JERUSALEM, March 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that Raphi Levy, Chief Financial Officer, will present in-person at the Jefferies Radiopharma Innovation Summit in New York City on Monday, April 3rd, 2023.
| Event: | Jefferies Radiopharma Innovation Summit |
| Date: | Monday, April 3rd, 2023 |
| Time: | 3:30-4:00 PM ET |
| Location: | Jefferies, NY, New York |
Raphi Levy will also be available for 1x1 investor meetings at the conference. Please reach out to your Jefferies representative to schedule.
About Alpha Tau Medical, Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.56 |
| Daily Change: | 0.21 6.27 |
| Daily Volume: | 606,937 |
| Market Cap: | US$249.560M |
December 18, 2024 December 17, 2024 November 19, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
